Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Chimica et Natura Acta Pharmacology and Clinical Pharmacy Research
Nurviana, Destawesty
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Environmental Science Materials Science & Nanotechnology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Adverse Drug Reaction of Angiotensin Receptor Blockers (Valsartan, Candesartan, Losartan): a Systematic Review Nurviana, Destawesty; Destiani, Dika P.
Pharmacology and Clinical Pharmacy Research Vol 9, No 3 (2024)
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/pcpr.v9i3.56906

Abstract

Hypertension is a significant global health problem, with a growing prevalence worldwide. The most commonly documented ADRs of hypertension medication in primary care records include those associated with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). The purpose of this paper is to review and evaluate the potential adverse drug reactions (ADRs) associated with the use of Angiotensin Receptor Blockers (ARBs), specifically valsartan, candesartan, and losartan in the management of hypertension and related diseases. We conducted a systematic review of randomized controlled trial articles that involved valsartan, candesartan, and losartan monotherapy compared with placebo or other standard antihypertensive drugs. PubMed and Google Scholar databases were used in the search for articles in May 2024 and 21 articles were included in this review. This study comprised 21 randomized controlled trials. The study participants' ages ranged from 34.4 years to 76 years. Sample sizes ranged from 16 to 1381 patients with a total 4606 patients. A total of 44 ADRs were observed and the most likely ADRs were headache, dizziness, hypotension, hyperkalemia, nausea, upper respiratory tract infection, and fatigue. Generally, the ADRs that occurred were not fatal and did not lead to discontinuation of therapy. The safety and tolerability profiles of ARBs are among the best for antihypertensive drugs, then overall, the comparison of ARB agents between valsartan, candesartan, and losartan in this class is similar. The most frequent adverse events in the group receiving therapy include headache, dizziness, hypotension, hyperkalemia, nausea, nasopharyngitis, and fatigue. 
Identifikasi Senyawa Aktif Rimpang Kunyit (Curcuma longa L.) sebagai Kandidat Antikanker Melalui Studi In Silico terhadap Reseptor Lymphocyte-Specific Protein Tyrosine Kinase Maharani, Devita Salsa; Redjeki, Sarah Gustia; Emamia, Evelyn Stepania; Mulyadi, Ananda Putri Aulia; Nurviana, Destawesty; Aulifa, Diah Lia; Amirah, Siti Rafa; Karim, Bilqisti Kanzabila
Chimica et Natura Acta Vol 12, No 1 (2024)
Publisher : Departemen Kimia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/cna.v12.n1.49427

Abstract

Curcuma longa L. dapat meningkatkan efek agen kemoterapi dalam pengobatan kanker kolorektal. Kanker kolorektal diekspresikan oleh peningkatan Lck pada sel epitel kolon. Perancangan obat dengan aktivitas sebagai inhibitor Lck dapat menjadi strategi penting untuk mengobati kanker kolorektal. Penelitian ini bertujuan untuk mengidentifikasi potensi aktivitas senyawa aktif yang terkandung dalam rimpang kunyit terhadap reseptor Lck melalui studi in silico metode penambatan molekuler sebagai kandidat obat antikanker, khususnya kanker kolorektal. Studi ini dilakukan dengan cara simulasi penambatan molekuler dengan AutoDock Tools-1.5.6., prediksi Lipinski dengan LigandScout, dan ADMET dengan PreADMET. Senyawa bidesmetoksikurkumin memiliki nilai ∆G sebesar -6,36 kkal/mol, konstanta inhibisi 13.71 µM dan interaksi dengan asam amino GLU317 dan MET319. Nilai HIA (Human Intestinal Absorption) dan Caco2 adalah 93,750% dan 21,402 nm/detik dengan nilai PPB (Plasma Protein Binding) dan BBB (Brain-blood Barrier) adalah 93,826% dan 0,785. Senyawa ini tidak bersifat mutagen namun karsinogen, serta memenuhi aturan Lipinski. Senyawa bidesmetoksikurkumin dapat dijadikan sebagai lead compound yang memiliki aktivitas terhadap reseptor Lck sebagai kandidat obat antikanker kolorektal.
Co-Authors Amirah, Siti Rafa Destiani, Dika P. Diah Lia Aulifa Emamia, Evelyn Stepania Karim, Bilqisti Kanzabila Maharani, Devita Salsa Mulyadi, Ananda Putri Aulia Redjeki, Sarah Gustia